Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Note: Funding Information: The ESMO Guidelines Committee thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. They also thank the European Cancer Patient Coalition and the following patient organisations for their review: BijnierNET/AdrenalNET. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. MF has declared conducting research sponsored by HRA Pharma, Millendo Therapeutics and Astellas Pharma; EB has declared participation as expert board and has received grants from HRA Pharma; HRH has received research support from HRA Pharma; MT has received honoraria and research grants from HRA Pharma; AB is currently conducting research sponsored by Ipsen and is a member of the speakers' bureau for Ipsen, Novartis and Advanced Accelerator Applications. GA, CdlF, GE, FP and Rdk have declared no potential conflicts of interest. Funding Information: MF has declared conducting research sponsored by HRA Pharma, Millendo Therapeutics and Astellas Pharma; EB has declared participation as expert board and has received grants from HRA Pharma; HRH has received research support from HRA Pharma; MT has received honoraria and research grants from HRA Pharma; AB is currently conducting research sponsored by Ipsen and is a member of the speakers' bureau for Ipsen, Novartis and Advanced Accelerator Applications. GA , CdlF , GE , FP and Rdk have declared no potential conflicts of interest.